StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Vir Biotechnology price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Vir Biotechnology's price to book ratio was 2.3× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.7× to 9.4×, with a median of 1.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.3×+1.2
2025Dec 31, 20251.1×+0.2
2024Dec 31, 20240.8×−0.1
2023Jul 31, 20231.0×−0.6
2022Dec 30, 20221.6×−4.7
2021Dec 31, 20216.3×+2.1
2020Dec 31, 20204.2×–

More Vir Biotechnology figures

See a number that looks wrong?